INTRODUCTIONHepatitis C virus (HCV) infection remains a serious public health issue worldwide. About 55‐85% of the population who have contact with HCV can develop chronic infection, which can lead to liver cirrhosis and furthermore hepatocellular carcinoma. Approximately, 130‐150 million people are affected globally and 700 000 people die each year due to HCV‐related liver complications. There are seven major genotypes, and more than 100 subtypes, of HCV from which genotype 1 is the most prevalent HCV type globally and responsible for about 60% of infections.Until recently, IFN‐based regimens were used to treat HCV, but these therapeutic regimens have been known to cause severe adverse events (AEs) and treatment discontinuation. Moreover, these regimens require weekly injection or complex dosing which can reduce the patients’ compliance. Recently, new direct‐acting antivirals (DAAs) with different mechanisms of action have been developed to provides much more efficacious and better‐tolerated therapeutic strategies than the older regimens. They can be used in combination with interferon (IFN) in shorter regimens or in combination with other DAAs in IFN‐free regimens to overcome the disadvantages of concomitant IFNs. Several IFN‐free regimens have been recommended by the World Health Organization (WHO), such as the combination of daclatasvir (DCV) and sofosbuvir (SOF)
Journal of Medical Virology – Wiley
Published: Jan 1, 2018
Keywords: ; ;
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.
All for just $49/month
Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.
Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.
It’s easy to organize your research with our built-in tools.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera